Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS - Get Free Report) passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $1.26 and traded as high as $1.39. Coherus BioSciences shares last traded at $1.35, with a volume of 2,880,481 shares traded.
Wall Street Analyst Weigh In
CHRS has been the subject of a number of research reports. HC Wainwright reissued a "buy" rating and issued a $7.00 price target on shares of Coherus BioSciences in a research note on Thursday, January 23rd. StockNews.com cut shares of Coherus BioSciences from a "buy" rating to a "hold" rating in a research note on Saturday, October 19th. Finally, Robert W. Baird boosted their price target on shares of Coherus BioSciences from $4.00 to $6.00 and gave the stock an "outperform" rating in a research note on Thursday, December 5th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $5.38.
View Our Latest Research Report on Coherus BioSciences
Coherus BioSciences Trading Down 5.9 %
The stock's fifty day moving average is $1.45 and its 200 day moving average is $1.25. The company has a market capitalization of $128.64 million, a P/E ratio of -13.88 and a beta of 0.81.
Institutional Investors Weigh In On Coherus BioSciences
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Los Angeles Capital Management LLC raised its holdings in Coherus BioSciences by 344.1% in the 3rd quarter. Los Angeles Capital Management LLC now owns 930,132 shares of the biotechnology company's stock worth $967,000 after purchasing an additional 720,672 shares in the last quarter. AQR Capital Management LLC bought a new position in Coherus BioSciences in the 2nd quarter worth $1,246,000. Marshall Wace LLP raised its holdings in Coherus BioSciences by 177.3% in the 2nd quarter. Marshall Wace LLP now owns 420,326 shares of the biotechnology company's stock worth $727,000 after purchasing an additional 268,763 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Coherus BioSciences by 159.2% in the 2nd quarter. Renaissance Technologies LLC now owns 394,828 shares of the biotechnology company's stock worth $683,000 after purchasing an additional 242,500 shares in the last quarter. Finally, XTX Topco Ltd raised its holdings in Coherus BioSciences by 74.5% in the 3rd quarter. XTX Topco Ltd now owns 473,517 shares of the biotechnology company's stock worth $492,000 after purchasing an additional 202,084 shares in the last quarter. 72.82% of the stock is currently owned by institutional investors.
Coherus BioSciences Company Profile
(
Get Free Report)
Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.
Recommended Stories
Before you consider Coherus BioSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Coherus BioSciences wasn't on the list.
While Coherus BioSciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
